Etigilimab with Nivolumab in Locally Advanced or Metastatic Solid Tumors

What is the Purpose of this Study?

If you choose to join this study, you will:
- Get the study drugs, etigilimab and nivolumab, by I.V. once every 2 weeks
- Give blood and urine samples
- Have regular CT or MRI scans
What is the Condition Being Studied?
Solid Tumors

Who Can Participate in this Study?

Adults with cancer that:

- Consists of solid tumors

- Is recurrent, locally advanced, or metastatic

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to see if the study drugs, etigilimab and nivolumab, are safe and effective for fighting your cancer.

Study Details

Full Title
A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Principal Investigator

Contacts
Protocol Number
IRB:
PRO00107599

NCT:
NCT04761198
ClinicalTrials.gov
View on ClinicalTrials.gov